Cangrelor Brand Name– Kengreal
What is Cangrelor
Cangrelor is an injectable P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.
Cangrelor is the only injectable P2Y12 inhibitor and is only administered during PCI. Following PCI, patients are transitioned to an oral P2Y12 inhibitor. Platelet inhibition occurs within 2 minutes of drug administration and returns to normal within 1 hour of discontinuation.
Cangrelor was approved by the FDA in June 2015.
- myocardial infarction prophylaxis
- percutaneous coronary intervention (PCI)
For use as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (i.e., myocardial infarction prophylaxis), repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor
- anaphylactic shock
- anaphylactoid reactions
- GI bleeding
- intracranial bleeding
- retroperitoneal bleeding
- obstetric delivery
- renal impairment
- Selective serotonin reuptake inhibitors